Clinical Trials List
2009-07-01 - 2012-08-31
Phase III
Terminated9
ICD-10C34.90
Malignant neoplasm of unspecified part of unspecified bronchus or lung
ICD-10C34.91
Malignant neoplasm of unspecified part of right bronchus or lung
ICD-10C34.92
Malignant neoplasm of unspecified part of left bronchus or lung
ICD-10C7A.090
Malignant carcinoid tumor of the bronchus and lung
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9162.9
Malignant neoplasm of bronchus and lung, unspecified
-
Trial Applicant
Boehringer Ingelheim
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- JIN-YUAN SHIH Division of Thoracic Medicine
- 陳冠宇 Division of Thoracic Medicine
- Chia-Chi Lin Division of Hematology & Oncology
- 林宗哲 Division of Hematology & Oncology
- 林育麟 Division of Hematology & Oncology
- PAN-CHYR YANG Division of Thoracic Medicine
- 廖唯昱 Division of Thoracic Medicine
- Chong-Jen Yu Division of Thoracic Medicine
- CHAO-CHI HO CHAO-CHI HO Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Peng-Chan Lin Division of Hematology & Oncology
- Ya-Ping Chen Division of Hematology & Oncology
- Chia-Jui Yen Division of Hematology & Oncology
- Wu-Chou Su Division of Hematology & Oncology
- Wen-Pin Su Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
90 participants
-
Global
2200 participants
